The New Routes Inside the Hospital
The announcement identifies two distinct journeys. Bone marrow specimens move from the hematology department to the laboratory, while donated blood travels from the donation center to the blood bank. These are deliveries between hospital units, rather than robots carrying out medical procedures.
That distinction makes the development easier to assess. The system’s immediate task is to move material through the hospital’s logistics network. Diagnosis, interpretation of laboratory findings and decisions about treatment remain separate from the transport function described in the release.
The project is operated through deliverz.ai, a subsidiary of Gix. The company said its software coordinates autonomous robots and human resources through a central platform.
How the Existing Project Is Expanding
Gix described the new services as an expansion of its continuing work at Sheba, rather than the hospital’s first use of logistics robots. The announcement said thousands of missions had already been completed across indoor and outdoor environments.
The same management platform serves multiple departments and delivery uses, according to the company. Its described functions include assigning tasks according to location, priority and availability, allowing different delivery resources to be coordinated through one operations system.
The release did not provide a separate count of completed blood deliveries or bone marrow specimen journeys. The broader mission total therefore should not be mistaken for a measured record of the newly announced routes.
What Sheba Says the Project Is For
Michal Kaplansky, identified in the announcement as Sheba’s head of innovation for human experience, operations and logistics, described autonomous logistics as operational infrastructure. Her statement emphasized patient flow and giving staff more time for patient care.
Gix said the expanded workflows aim to reduce transport delays, improve traceability and support earlier availability of diagnostic results. These are the purposes stated for the project. The announcement did not publish an independent comparison showing how much the new routes have shortened laboratory turnaround times.
For readers, that separates a confirmed service expansion from a clinical outcome claim. The routes have been announced as operating; a quantified improvement in diagnosis or treatment has not been established by the material reviewed.
The Israeli Achievement Behind the Announcement
The development connects an Israeli technology company’s coordination software with routine work at an Israeli medical center. Its significance lies in applying automation to an existing hospital operation, with specific collection points and destinations, rather than presenting an unspecified future concept.
The company’s account also describes coordination between people and machines. That is a more precise explanation than suggesting that a hospital has become fully autonomous or that medical staff have been replaced. Neither claim appears in the announcement.
The evidence for the expansion is a company release carrying a named Sheba official’s statement. It supports reporting what the company announced, while requiring attribution for its operational claims.
What Happens Next
Gix said further expansion is planned for additional medication deliveries and transport of diagnostic specimens. It did not provide implementation dates or a complete list of the departments involved in those next stages.
Future reporting can assess those additions through confirmed routes and published performance measurements. For now, the concrete change is the inclusion of donated blood and bone marrow specimens in the hospital’s existing robotic delivery network.
